摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2Z,2'Z)-N,N'-(1,3-phenylenebis(methylene))bis(2-cyano-3-(6-methoxypyridin-2-yl)acrylamide) | 1567834-51-8

中文名称
——
中文别名
——
英文名称
(2Z,2'Z)-N,N'-(1,3-phenylenebis(methylene))bis(2-cyano-3-(6-methoxypyridin-2-yl)acrylamide)
英文别名
(Z)-2-cyano-N-[[3-[[[(Z)-2-cyano-3-(6-methoxypyridin-2-yl)prop-2-enoyl]amino]methyl]phenyl]methyl]-3-(6-methoxypyridin-2-yl)prop-2-enamide
(2Z,2'Z)-N,N'-(1,3-phenylenebis(methylene))bis(2-cyano-3-(6-methoxypyridin-2-yl)acrylamide)化学式
CAS
1567834-51-8
化学式
C28H24N6O4
mdl
——
分子量
508.536
InChiKey
DKENYAWRLJPHPZ-JZTLMNBPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    38
  • 可旋转键数:
    10
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    150
  • 氢给体数:
    2
  • 氢受体数:
    8

反应信息

  • 作为产物:
    参考文献:
    名称:
    Degrasyn-like symmetrical compounds: Possible therapeutic agents for multiple myeloma (MM-I)
    摘要:
    A series of degrasyn-like symmetrical compounds have been designed, synthesized, and screened against B cell malignancy (multiple myeloma, mantle cell lymphoma) cell lines. The lead compounds T5165804 and CP2005 showed higher nanomolar potency against these tumor cells in comparison to degrasyn and inhibited Usp9x activity in vitro and in intact cells. These observations suggest that this new class of compounds holds promise as cancer therapeutic agents. (C) 2014 Published by Elsevier Ltd.
    DOI:
    10.1016/j.bmc.2013.12.048
点击查看最新优质反应信息

文献信息

  • Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
    申请人:Emory University
    公开号:EP2364702A2
    公开(公告)日:2011-09-14
    A composition is provided which comprises one or more Kinase inhibitors for use for preventing or treating a pathogenic infection caused by a broad array of pathogens in a patient in need thereof.
    本发明提供了一种组合物,其中包含一种或多种激酶抑制剂,用于预防或治疗由多种病原体引起的病原体感染。
  • Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof
    申请人:Emory University
    公开号:EP2471529A2
    公开(公告)日:2012-07-04
    A composition is provided which comprises one or more Kinase inhibitors for use for preventing or treating a pathogenic infection caused by a broad array of pathogens in a patient in need thereof.
    本发明提供了一种组合物,其中包含一种或多种激酶抑制剂,用于预防或治疗由多种病原体引起的病原体感染。
  • KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF
    申请人:Kalman Daniel
    公开号:US20120302565A1
    公开(公告)日:2012-11-29
    The present invention provides compositions and methods of use thereof to prevent and/or treat pathogenic infection. In particular, the present invention provides the use of kinase inhibitors to inhibit kinases that involve in pathogen-host cell interactions that are associated with or cause pathogenic infections, therefore, to effectively prevent and/or treat pathogenic infections with far less likely to engender resistance as compared to conventional antibiotics and anti-viral drugs. The present invention further provides the use of kinase inhibitors for the treatment of acute pathogenic infections for a short period of time to avoid toxicities that may caused by long term use of these kinase inhibitors.
  • US8268809B2
    申请人:——
    公开号:US8268809B2
    公开(公告)日:2012-09-18
  • Degrasyn-like symmetrical compounds: Possible therapeutic agents for multiple myeloma (MM-I)
    作者:Zhenghong Peng、David S. Maxwell、Duoli Sun、Basvoju A. Bhanu Prasad、Paul T. Schuber、Ashutosh Pal、Yunming Ying、Dongmei Han、Liwei Gao、Shimei Wang、Alexander Levitzki、Vaibhav Kapuria、Moshe Talpaz、Matthew Young、Hollis D. Showalter、Nicholas J. Donato、William G. Bornmann
    DOI:10.1016/j.bmc.2013.12.048
    日期:2014.2
    A series of degrasyn-like symmetrical compounds have been designed, synthesized, and screened against B cell malignancy (multiple myeloma, mantle cell lymphoma) cell lines. The lead compounds T5165804 and CP2005 showed higher nanomolar potency against these tumor cells in comparison to degrasyn and inhibited Usp9x activity in vitro and in intact cells. These observations suggest that this new class of compounds holds promise as cancer therapeutic agents. (C) 2014 Published by Elsevier Ltd.
查看更多